🕒 Last update: loading…16/11/2026

Stock AbCellera Biologics Inc. ABCL

AbCellera Biologics Inc. — Investlytic score 2/5 on the five criteria.

-
-
40/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 2/5 criteria met. Data as of 01/11/2026.

  • ❌ Price trend failed
  • ⚠️ Mixed growth
  • ✅ Debt passed
  • ❌ P/E failed
  • ✅ Correction passed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2020 → 2021: -64.46%

Price change 2021 → 2022: -29.16%

Price change 2022 → 2023: -43.63%

Price change 2023 → 2024: -48.69%

Price change 2024 → 2025: 16.72%

Price change 2025 → 2026: 258.77%

Price change 2026 (year to date): 257.73%

Financial growth

Revenue CAGR (8 years): 35.78%

Earnings CAGR (8 years): N/A

Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.

Debt

Debt-to-equity ratio: 0.15

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -22.72

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 17.21% from the high over 6 months.

Correction between 10.0% and 20.0% (target range).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
AbCellera Biologics Inc.–0.15+35.8 %🔒
Legend Biotech Corporation–0.41+60.3 %–
Virbac S.A.20.00.26+6.5 %★ 4/5
Option Care Health, Inc.18.40.96+18.7 %–
Merit Medical Systems, Inc.22.30.57+11.5 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by AbCellera Biologics Inc. over the latest fiscal years.

Revenue
75.1 m USD
fiscal year 2025
Net income
-146 m USD
fiscal year 2025
Net margin
-194.9 %
fiscal year 2025
Average annual growth
-20.3 %
Revenue growth over 5 years
Market cap
3.8 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
2020233 m119 m51.0 %n/a
2021375 m153 m40.9 %+60.9 %
2022485 m159 m32.7 %+29.4 %
202338.0 m-146 m-385.0 %-92.2 %
202428.8 m-163 m-564.8 %-24.2 %
202575.1 m-146 m-194.9 %+160.6 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by AbCellera Biologics Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
average accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
5.36
safe zone (above 2.99)
Piotroski Score
3 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
0.22 x
low debt
Fiscal year20212022202320242025
Cash and investments723 m886 m761 m626 m534 m
Total Debt40.1 m82.3 m77.4 m65.4 m143 m
Net Debt-436 m-304 m-55.9 m-91.0 m14.7 m
Equity1.0 bn1.2 bn1.2 bn1.1 bn967 m
Total assets1.3 bn1.5 bn1.5 bn1.4 bn1.4 bn
Operating cash flow245 m277 m-43.9 m-109 m-131 m
Investments (capex)58.5 m72.7 m77.5 m78.4 m42.8 m
Free cash-flow186 m205 m-121 m-187 m-174 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-24.21 x
Price / book value3.48 x
Return on Equity (ROE)-15.3 %
Return on Invested Capital (ROIC)-12.2 %
Net margin-218.5 %
Debt / equity0.13 x
Current ratio12.43 x
Free cash-flow yield-2.4 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.

+

Valuation and competitors

AbCellera Biologics Inc. compared with its sector on the same exchange and with its main competitors.

Sector median P/E
20.8
healthcare, Nasdaq
Sector over 10 years
28.2
10-year median, range 20.4 to 45.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
AbCellera Biologics Inc.3.8 bnn/a-194.9 %
Absci Corporation ABSI1.7 bnn/a-4,113.7 %
Ginkgo Bioworks Holdings, Inc. DNA760 mn/a-183.8 %
Sector median (Nasdaq)20.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering AbCellera Biologics Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
13 analysts
Average price target
17.33 USD
from n/a to n/a, 7 targets over 12 months
Gap with the share price
+45.9 %
price 11.88 USD on 06/11/2026

Breakdown of ratings

strong buy 0buy 12hold 1sell 0strong sell 0

Average target over the last 3 months: 17.33 USD (3 targets).

Track record against expectations: reported EPS above consensus 8 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.

+

Dividends and earnings

AbCellera Biologics Inc.: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Earnings releases

DatePublished EPSExpected EPSSurprise
09/11/2026-0.13-0.17n/a
05/08/2026-0.18-0.16n/a
11/05/2026-0.14-0.22n/a
24/02/2026-0.03-0.18n/a
06/11/2025-0.19-0.17n/a
07/08/2025-0.12-0.17n/a

Factual data: ex-dividend history and earnings calendar, as of 15/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in AbCellera Biologics Inc.

Free float
64.5 %
share of freely traded shares
Large funds tracked
18
hold the stock as of 2026Q2
Executives (insiders)
6 / 0
6 purchases, 0 sales in 130 days

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
Capital World Investors13.6 m107 m0.0 %+1.7 %2026Q2
Two Sigma Investments10.4 m81.9 m0.1 %-1.2 %2026Q2
Bank of America6.1 m48.2 m0.0 %+104.7 %2026Q2
BlackRock3.8 m29.9 m0.0 %-5.8 %2026Q2
Citadel Advisors3.2 m24.9 m0.0 %+133.1 %2026Q2
Tudor Investment2.1 m16.2 m0.1 %-9.3 %2026Q2
Marshall Wace1.9 m14.9 m0.0 %+428.9 %2026Q2
Morgan Stanley1.7 m13.1 m0.0 %-25.0 %2026Q2

Latest insider transactions

DatePersonSideAmount
13/11/2026Booth Andrewpurchase97,438 USD
12/11/2026Thermopylae Holdings Ltd.purchase698,920 USD
24/08/2026Hayden Michael Rpurchase570,442 USD
18/08/2026Montalbano John S.purchase110,300 USD
14/08/2026Booth Andrewpurchase383,904 USD
12/08/2026Hayden Michael Rpurchase481,033 USD

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 16/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 11/12/2020
ISIN code
CA00288U1066
Workforce
596
full-time employees
Chief executive
Carl L.G. Hansen

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about AbCellera Biologics Inc.

What is the AbCellera Biologics Inc. share price?

Latest recorded price: 11.49 USD on 13/11/2026, for a market cap of 3.8 bn USD.

What is the revenue of AbCellera Biologics Inc.?

75.1 m USD for fiscal year 2025, with net income of -146 m USD (net margin -194.9 %).

What do analysts say about AbCellera Biologics Inc.?

Out of 13 analysts: 12 buy or strong buy, 1 hold, 0 sell or strong sell. Average price target: 17.33 USD, i.e. +45.9 % from the share price.

Is AbCellera Biologics Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN CA00288U1066).

How many employees does AbCellera Biologics Inc. have?

596 full-time employees according to the latest published profile.

Who runs AbCellera Biologics Inc.?

Carl L.G. Hansen is the company's chief executive.

Which large funds own AbCellera Biologics Inc.?

As of 2026Q2, among the large funds tracked: Capital World Investors, Two Sigma Investments, Bank of America, BlackRock, Citadel Advisors.

07

Similar stocks